β-Carbonic Anhydrase as a Target for Eradication of Mycobacterium tuberculosis
Open Access Journal of Pharmaceutical Research · 2017
DOI: 10.23880/oajpr-16000106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Open Access Journal of Pharmaceutical Research, 2017. Verfasst von Noor HN.
Abstract (Originalsprache)
Tuberculosis is one of the ancient infectious disease which has been re-emerged, long after the medical establishment was considered it to be declined [1]. The re-emergence is particularly due to the development of resistance to the ordinary therapy [2]. The appearance of multi-drug resistance tuberculosis (MDR-TB), and extensively drug resistance tuberculosis (XDR-TB), made a great obstacle for controlling of this infectious disease [3].Tuberculosis is a global airborne disease, which caused by gram positive bacterium Mycobacterium tuberculosis (Mtb) [4]. This bacteria is non-motile, nonspore forming, aerobic rods, its cell wall is highly hydrophobic, due to richness with different types of lipids [5]. The ordinary anti-tuberculosis drugs can be classified into; First line drugs; include Isoniazide (INH), Rifampicin, Ethambutol, Pyrazinamide, and Streptomycin [6]. Second line drugs; include Amikacin, Capreomycin, Cycloserine, Thiacetazone, Ethionamide, Para-aminosalicylic acid, and quinolones as ciprofloxacin.
Zitieren
APA
HN, N. (2017). β-Carbonic Anhydrase as a Target for Eradication of Mycobacterium tuberculosis. Open Access Journal of Pharmaceutical Research. https://doi.org/10.23880/oajpr-16000106
Vancouver
HN N. β-Carbonic Anhydrase as a Target for Eradication of Mycobacterium tuberculosis. Open Access Journal of Pharmaceutical Research. 2017. doi:10.23880/oajpr-16000106
BibTeX
@article{HN2017,
author = {HN, Noor},
title = {β-Carbonic Anhydrase as a Target for Eradication of Mycobacterium tuberculosis},
journal = {Open Access Journal of Pharmaceutical Research},
year = {2017},
doi = {10.23880/oajpr-16000106}
}
EUVIMED